Aml Cell Lines
Aml Cell Lines - Related Videos
01:16
Cell Lines
0 Views •
2023
A cell line is a population of cells grown in vitro that can be subcultured over several generations. Normal cells cease to divide after a certain number of cell divisions, a process known as replicative senescence. This number, called the Hayflick limit, was conceptualized by Leonard Hayflick in 1961 when he observed that fetal cells grown in culture could only divide 40-60 times. This limit is due to the shortening of the telomeres during each round of cell division, preventing cell division...
11:39
Chromatin Immunoprecipitation (ChIP) in Mouse T-cell Lines
0 Views •
Cited by 13 •
2017
This work describes a protocol for chromatin immunoprecipitation (ChIP) using a mature mouse T-cell line. This protocol is suitable to investigate the distribution of specific histone marks at specific promoter sites or genome-wide.
12:59
Derivation of Stem Cell Lines from Mouse Preimplantation Embryos
0 Views •
Cited by 1 •
2017
This article describes a protocol to efficiently derive and culture pluripotent stem cell lines from mouse embryos at the blastocyst stage.
03:14
Phenotyping EBV-Infected Cell Lines Using Flow Cytometry
0 Views •
2026
Source: Xu, C., et al. An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection. J. Vis. Exp. (2018).This video demonstrates the phenotyping of EBV-infected T and NK cell lines using flow cytometry, highlighting the preparation, antibody staining, and analysis steps to identify lineage-specific surface markers. It shows how marker profiles confirm distinct T-cell and NK-cell populations.
17:59
Derivation of Thymic Lymphoma T-cell Lines from Atm-/- and p53-/- Mice
0 Views •
Cited by 11 •
2011
In this video we demonstrate a protocol to establish mouse thymic lymphoma cell lines. By following this protocol, we have successfully established several T-cell lines from Atm-/- and p53-/- mice with thymic lymphoma.
FAQs
Their retained disease-associated molecular abnormalities allow researchers to relate cellular behavior to underlying genetic features. By examining proliferation, survival, differentiation, or signaling in a controlled culture system, investigators can compare how particular molecular characteristics correspond with observable phenotypes. This approach helps clarify leukemia biology while reducing variability between experiments performed under comparable conditions.
Defined culture conditions improve experimental consistency by providing a controlled setting for maintaining cells and measuring their responses. When conditions remain comparable, differences in proliferation, survival, differentiation, or treatment response are more readily attributed to the experimental variable rather than uncontrolled culture variation. This reproducibility supports systematic comparisons across experiments and therapeutic strategies.
Researchers should interpret each line in relation to its retained molecular abnormalities and disease-associated characteristics rather than treating all lines as interchangeable. Comparing several lines can reveal relationships between genotype and cellular behavior, while validation helps establish how closely a given model reflects particular AML subtypes. This distinction strengthens conclusions about leukemia mechanisms and treatment responses.
A study generally maintains the cells under defined culture conditions, exposes them to the experimental treatment or condition, and then measures outcomes such as proliferation, survival, differentiation, or signaling. Researchers can compare treated and untreated responses, examine differences among lines, and use the resulting data to evaluate biological mechanisms or therapeutic strategies.
They are useful when investigators need reproducible, controlled models for examining how candidate compounds affect malignant blood-cell behavior. Researchers can measure changes in proliferation, survival, differentiation, or signaling and compare responses across cell lines. These experiments help prioritize compounds and therapeutic strategies before evaluation in more complex models, while retaining a direct connection to leukemia biology.
Their controlled experimental setting allows investigators to examine differences in treatment response and identify patterns associated with reduced sensitivity. By comparing cellular outcomes after exposure to therapeutic compounds, researchers can study resistance-related behavior alongside proliferation, survival, differentiation, or signaling changes. Findings can inform comparisons of treatment strategies before work advances to more complex experimental models.